Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 21, Issue 2, 1997, Pages 299-311

  Lane, Hsien Yuan ^a,b   Lin, Hsin Nan ^c   Hu, Oliver Yoa Pu ^a   Chen, Chiao Chicy ^b   Jann, Michael W ^d   Chang, Wen Ho ^b,c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d MERCER UNIVERSITY   (United States)

Author keywords

haloperidol; plasma concentration; red blood cell concentration; reduced haloperidol

Indexed keywords

HALOPERIDOL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA;

ADOLESCENT; ADULT; EXTRAPYRAMIDAL TRACTS; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED;

EID: 0030993544     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(97)00007-9     Document Type: Article

References (32)

1. ALTAMURA, A.C. (1993) A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia with particular reference to drug resistance. Schizophr. Res. 8:187-198.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: The Association.
3. BALDESSARINI, R.J., COHEN, B.M. and TEICHER, M.H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45:79-91.
4. Bowen, W.D., Moses, E.L., Tolentino P.J. and Walker, J.M. (1990) Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D2 receptor. Eur. J. Pharmacol. 177:111-118.
5. Brent, P.J. (1994) Haloperidol and reduced haloperidol induced exacerbation of the dystonia produced by kappa opioid U50, 488H in guinea pigs correlate with inhibition of signa binding sites. Neuropsychopharmacology 10:134S.
6. CHANG, W.H. (1992) Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatnent? Psychopnamacology 106:289-296.
7. CHANG, W.H., HWU, H.G., LANE, H.Y., LIN, S.K., CHEN, T.Y., CHEN, H., WEI, H.L. and LIN, H.N. (1991) Dose-dependent reduced haloperidol/haloperidol ratios in Schizophrenic patient. Psychiatry Res. 38:215-225.
8. CHANG, W.H., LIN, S.K., JANN, M.W., LAM, Y.W.F., CHEN, T.Y., CHEN, C.T., HU, W.H. and YEH E.K. (1989) Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. Biol. Psychiatry 26:239-249.
9. CONLEY, R., AN NGUYEN, J. and TAMMINGA, C. (1991) Haloperidol kinetics and clinical response. Schizophr. Res. 4, 287.
10. DODDI, S., RIFKIN, A., KARAJGI, B., COOPER, T. and BORENSTEIN, M. (1994) Blood levels of haloperidol and clinical outcome in schizophrenia. J. Clin. Psychopharnacol. 14:187-195.
11. DYSKEN, M.W., JOHNDON, S.B., HOLDEN, L., KUSKOWSKI, M., OFSTEHAGE, J., SKARE, S. and VATASSERY, G. (1992) Haloperidol and reduced haloperidol in saliva and blood. J. Clin. Psychopharmacol. 12:186-190.
12. GARVER, D.L., DEKIRMENJIAN, H., DAVIS, J.H., CASPER, R. and ERICKSEN, S. (1977) Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am. J. Psychiatry 134:304-307.
13. GUY, W. (1976) ECDEU Assessment manual for psychopharmacology. Rockville, MD, US Dept of Health, Education and Welfare, Public Health Service. Alcohol, Drug Abuse and Mental Health Administration, pp 217-244.
14. HUANG, H.F., JANN, M.W., TSENG, Y.T., CHUNG, M.C., CHIEN, C.P. and CHANG, W.H. (1995) Ketone reductase activity and reduced haloperidol/ haloperidol ratios in haloperidol treated Schizophrenic patients. Psychiatry Res. 57:101-108.
15. INABA, T. and KOVACS, J. (1989) Haloperidol reductase in human and guinea pig livers. Drug Metab. Disposit. 17:330-333.
16. INABA, T., KALOW, W., SOMEYA, T., TAKAHASHI, S., CHEUNG, S.W. and TANG, S.W. (1989) Haloperidol reduction can be assayed in human red blood cells. Canad. J. Physiol. Pharmacol. 67:1468-1469.
17. JANN, M.W., CHANG, W.H., DAVIS, C.M., CHEN, T.Y., LUGN, F.W., ERESHEFSKY, L., SAKLAD, S.R. and RICHARDS, A.L. (1989) Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry. Res 30, 45-52.
18. KANE, J.M., HONIGFELD, G., SINGER, J. and MELTZER, H.Y. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45:789-796.
19. KANE, J.M. and MARDER, S.R. (1993) Psychopharmacologic treatment of schizophrenia. Schizophr. Bull. 19:287-302.
20. KO, G.N., KORPI, E.R. and KIRCH, D.G. (1989) Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. J. Clin. Psychopharmacol. 9:186-190.
21. KORPI, E.R., PHELPS, B., GRANGER, H., CHANG, W.H., LINNOILA, M., MEEK, J.L. and WYATT, R.J. (1983) Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem. 29:624-628.
22. LANE, H.Y., HU, O.Y.P., JANN, M.W., DENG, H.C., LIN, H.N., and CHANG, W.H. (1996) Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry. Res (Submitted)
23. LANE, H.Y., LIN, H.N., HWU, H.G., JANN, M.W., HU, W.H. AND CHANG, W.H. (1995) Haloperidol plasma concentrations in Taiwanese psychiatric patients. J. Formos. Med. Assoc. 94: 671-678.
24. LINGJÆRDE, O., AHLFORS, U.G., BECH, P., DENCKER, S. J. and ELGEN, K. (1987) The UKU side effect rating scale. A new comprehensive ration scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76 (suppl. 334)
25. LLERENA, A., ALM, C., DAHL, M.L., EKQVIST, B. and BERTILSSON, L. (1992a) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit. 14, 92-97.
26. LLERENA, A., DAHL, M.L., EKQVIST, B. and BERTILSSON, L. (1992b) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit. 14, 261-264.
27. OVERALL, J.E. and GORHAM, D.R. (1962) Brief psychiatric rating scale (BPRS). Psychol. Rep. 10:799-812.
28. PALAO, D.J., ARAUXO, A., BRUNER, M., BERNARDO, M., HARO, J.M., FERRER, J. and GONZALEZ-MONCLUS, E. (1994) Haloperidol: Therapeutic window in schizophrenia. J. Clin. Psychopharmacol. 14:303-310.
29. SHIBASAKI, M., SOMEYA, T. and TAKAHASHI, S. (1993) Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population. Prog. Neuropsychopharmacol. Biol. Psychiatry 17:257-267.
30. TSANG, M.W., SHADER, R.I. AND GREENBLATT, D.J. (1994) Metabolism of haloperidol: clinical implications and unanswered questions. J. Clin. Psychopharmacol. 14: 159-162.
31. VOLAVKA, J. and COOPER, T.B. (1987) Review of haloperidol blood levels and clinical response: looking through the window. J. Clin. Psychopharmacol. 7:25-30.
32. VOLAVKA, J., COOPER, T.B., CZOBOR, P., BITTER, I., MEISNER, M., LASKA, E., GASTANAGA, P., KRAKOWSKI, M., CHOU, J., CROWNER, M. and DOUYON, R. (1992) Haloperidol blood levels and clinical effects. Arch. Gen. Psychiatry 49:354 361.